Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5069221 | 0.86 | INPP5A (0.39) | KDM4EMAPTHPGDTSHRKDM1A | |
| SCHEMBL28656403 | 0.77 | SLC18A3 (0.44) | TSHRKDM1AMAOAMAOBSLC6A2 | |
| SCHEMBL5066891 | 0.76 | MEN1 (0.40) | MAPTTSHR | |
| SCHEMBL17158548 | 0.72 | INPP5A (0.37) | KDM1AMAOAMAOBSLC6A2SLC6A4 | |
| SCHEMBL5069081 | 0.71 | INPP5A (0.30) | — | |
| SCHEMBL5066812 | 0.69 | EPHX1 (0.33) | — | |
| SCHEMBL1195857 | 0.69 | TSHR (0.64) | KDM4ETSHRMAOBSLC6A2SLC6A4 | |
| SCHEMBL8675407 | 0.69 | TSHR (0.48) | TSHRKDM1AMAOAMAOBSLC6A2 | |
| SCHEMBL1265907 | 0.69 | TSHR (0.48) | TSHRKDM1AMAOAMAOBSLC6A2 | |
| SCHEMBL1265905 | 0.69 | TSHR (0.48) | TSHRKDM1AMAOAMAOBSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365215-B2 | Process for preparing 4-aminotetrahydropyran compound and an acid salt thereof, synthetic intermediate thereof and process for preparing the same | UBE INDUSTRIES, LTD. (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20070106083-A1 | Process for preparing 4-aminotetrahydropyran compound and an acid salt thereof, synthetic intermediate thereof and process for preparing the same | UBE INDUSTRIES, LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1661894-A1 | PROCESS FOR PRODUCTION OF 4-AMINOTETRAHYDROPYRANS AND SALTS THEREOF WITH ACIDS, INTERMEDIATES FOR THE PROCESS, AND PROCESS FOR PRODUCTION THEREOF | Ube Industries, Ltd. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106083-A1 | Process for preparing 4-aminotetrahydropyran compound and an acid salt thereof, synthetic intermediate thereof and process for preparing the same | PAH, HPD, REN | KDM4E 1328/4885MAPT 2628/4885HPGD 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.